Selective fiasma treatment

A method according to any preceding claim, wherein the method comprises not administering to the subject a non-FIASMA for the treatment or prevention of any disease or disorder.

A method according to any preceding claim, wherein the disease is not atherosclerosis or a disease caused by atherosclerosis.

A method according to any preceding claim, wherein the FIASMA is selected from the group consisting of:

• Alverine, Amiodarone, Amitriptyline, Amlodipine, Aprindine, Astemizole, AY-9944, Benztropine, Bepridil, Biperiden, Camylofine, Carvedilol, Cepharanthine, Chlorpromazine, Chlorprothixene, Cinnarizine, Clemastin, Clofazimine, Clomiphene, Clomipramine, Cloperastine, Connesine, Cyclobenzaprine, Cyproheptadine, Desipramine, Desloratadine, Dicyclomine, Dilazep, Dimebon, Doxepin, Drofenine, Emetine, Ethopropazine, Fendiline, Flunarizine, Fluoxetine, Flupenthixol, Fluphenazine, Fluvoxamine, Hydroxyzine, Imipramine, Lofepramine, Loperamid, Loratadine, Maprotiline, Mebeverine, Mebhydroline, Mibefradil, Norfluoxetine, Nortriptyline, Paroxetine, Penfluridol, Perhexiline, Perphenazine, Pimethixene, Pimozide, Promazin, Promethazin, Protriptyline, Quinacrine, Sertindole, Sertraline, Solasodine, Suloctidil, Tamoxifen, Terfenadine, Thioridazin, Tomatidine, Trifluoperazine, Triflupromazine, Trimipramine, Zolantidine, and combinations thereof.

A method according to any preceding claim, wherein the FIASMA is a selective serotonin reuptake inhibitor.

A method according to any preceding claim, wherein the FIASMA is Paroxetine or Fluoxetine.

A method according to any preceding claim, wherein the subject is a non-human animal.

A method of treating or preventing depression or anxiety in a subject having atherosclerosis, wherein the depression or anxiety is treatable or preventable by a functional inhibitor of acid sphingomyelinase (FIASMA) and alternatively by a non-FIASMA, wherein the method comprises:

• selectively administering to the subject a FIASMA for the treatment or prevention of the depression or anxiety and not administering to the subject a non-FIASMA for the treatment or prevention of the depression or anxiety.

A functional inhibitor of acid sphingomyelinase (FIASMA) for use in treating or preventing a disease in a subject having atherosclerosis,

• wherein the disease is treatable or preventable by the FIASMA and alternatively by a non-FIASMA, and
• wherein the non-FIASMA is not administered to the subject for the treatment or prevention of the disease.

A functional inhibitor of acid sphingomyelinase (FIASMA) for use in treating or preventing depression or anxiety in a subject having atherosclerosis,

• wherein the depression or anxiety is treatable or preventable by the FIASMA and alternatively by a non-FIASMA, and
• wherein the non-FIASMA is not administered to the subject for the treatment or prevention of the depression or anxiety.

A method of treating or preventing a disease in a subject having atherosclerosis, wherein the disease is treatable or preventable by a functional inhibitor of acid sphingomyelinase (FIASMA) and alternatively by a non-FIASMA, wherein subject is being administered a non-FIASMA for the treatment or prevention of the disease, wherein the method comprises:

• ceasing administration of the non-FIASMA for the treatment or prevention of the disease, and
• selectively administering to the subject a FIASMA for the treatment or prevention of the disease and not administering to the subject a non-FIASMA for the treatment or prevention of the disease.

A method of treating or preventing a disease in a subject having atherosclerosis, wherein the disease is treatable or preventable by a functional inhibitor of acid sphingomyelinase (FIASMA) and alternatively by a non-FIASMA, wherein the method comprises:

• determining that the patient is at elevated risk of MACE, and
• selectively administering to the subject a FIASMA for the treatment or prevention of the disease and to reduce the risk of MACE, and not administering to the subject a non-FIASMA for the treatment or prevention of the disease.

A method of treating or preventing a disease in a subject having atherosclerosis, wherein the disease is treatable or preventable by a functional inhibitor of acid sphingomyelinase (FIASMA) and alternatively by a non-FIASMA, wherein the method comprises:

• selectively administering to the subject a FIASMA for the treatment or prevention of the disease and to reduce the risk of MACE or avoid an increased risk of MACE, and not administering to the subject a non-FIASMA for the treatment or prevention of the disease.

A method of reducing the risk of a MACE in a subject,

• wherein the subject has atherosclerosis and is being treated for a secondary disease that is not atherosclerosis, wherein the method comprises:
• determining that the subject is at elevated risk for MACE, and
• selectively administering a FIASMA for the treatment or prevention of the secondary disease and to reduce the risk of MACE, and not administering to the subject a non-FIASMA for the treatment or prevention of the secondary disease.